Remaxol® in Mechanical Jaundice of Non-malignant Origin

• Status: Completed
• Trial end date: 2020-04-13
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and efficacy of Remaxol (succinate + methionine + inosine + nicotinamide; POLYSAN Ltd., Russia) infusions at dose 400 and 800 ml to treat mechanical jaundice of non-tumor cause during the first week after surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company; Scientific Technological Pharmaceutical Firm Polysan, Ltd.
• Treatments: Niacin; Niacinamide; Nicotinic Acids; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

1. Presence of signed informed consent for participation in the study.

2. Men and women over the age of 18 (incl.).

3. Obstructive jaundice, verified by enlargement of intrahepatic bile ducts with proven non-tumor obstruction of extrahepatic bile ducts.

4. Duration of mechanical jaundice 15 days or less.

5. The level of total bilirubin in the blood from 5-fold to 20-fold exceeding normal.

6. Laboratory data corresponding to the following cutoff limits :

• hemoglobin ≥90 g / l;

• neutrophils ≥ 1.5x109 / l;

• Platelets ≥ 75 x 109 / L;

• AsAT and / or AlAT above 3 х normal but less than 20 х normal

• Serum creatinine not exceeding 2 × normal,

• Serum potassium within normal limits

7. Negative urine test for pregnancy in women of reproductive age.

8. Consent to use adequate methods of contraception or for complete abstinence from sexual activity for the period of the study.

9. Consent to abstain completely from alcohol intake during the study period.

Exclusion Criteria:

1. Tumor causing the obstruction of the bile ducts or the presence of any other malignancy at the time of randomization.

2. The need for another radical surgery within 2 weeks from the planned date of randomization.

3. Acute destructive pancreatitis, diffuse or diffuse peritonitis, sepsis.

4. Preexisting liver cirrhosis.

5. Exacerbation of the chronic peptic ulcer.

6. Ongoing bleeding.

7. Presence of clinically significant cardiovascular diseases: chronic cardiac insufficiency III-IV functional class by NYHA, uncontrolled arterial hypertension, acute stroke or acute myocardial infarction in the previous 3 months, unstable angina, uncontrolled arrhythmia and severe heart rhythm disturbances.

8. Any other decompensated disease.

9. Pregnancy or lactation.

10. Hypersensitivity to any component of the study drug / placebo and / or intolerance to any component of the study drug / placebo.

11. Regular admission of medications prohibited or not permitted by the study protocol within 4 weeks prior to enrollment.

12. Concomitant chronic systemic immune or hormonal therapy.

13. Gout.

14. Alcohol and/or drug dependence.

15. Active tuberculosis, HIV infection, syphilis, acute viral hepatitis.

16. Any other conditions / diseases that may interfere with the patient's compliance with the requirements of the Protocol.

17. Mental, physical and other reasons that do not allow the patient to comply with the requirements of the study protocol.

18. Any other significant (by judgement of the investigator) condition that prevents the patient from entering the study.

19. Participation in any clinical trial in the previous 3 months.

20. Staff of the research center and their family members.